189 related articles for article (PubMed ID: 11163834)
1. Human uterine and ovarian expression of growth hormone-releasing hormone messenger RNA in benign and malignant gynecologic conditions.
Khorram O; Garthwaite M; Grosen E; Golos T
Fertil Steril; 2001 Jan; 75(1):174-9. PubMed ID: 11163834
[TBL] [Abstract][Full Text] [Related]
2. Uterine and ovarian aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) mRNA expression in benign and malignant gynaecological conditions.
Khorram O; Garthwaite M; Golos T
Mol Hum Reprod; 2002 Jan; 8(1):75-80. PubMed ID: 11756572
[TBL] [Abstract][Full Text] [Related]
3. Expression and possible implication of growth hormone-releasing hormone receptor splice variant 1 in endometriosis.
Fu L; Osuga Y; Yano T; Takemura Y; Morimoto C; Hirota Y; Schally AV; Taketani Y
Fertil Steril; 2009 Jul; 92(1):47-53. PubMed ID: 18684444
[TBL] [Abstract][Full Text] [Related]
4. The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line.
Annunziata M; Grande C; Scarlatti F; Deltetto F; Delpiano E; Camanni M; Ghigo E; Granata R
Fertil Steril; 2010 Aug; 94(3):841-9. PubMed ID: 19524226
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of estrogen receptor alpha and beta messenger ribonucleic acid levels in normal endometrium and ovarian endometriotic cysts using a real-time reverse transcription-polymerase chain reaction assay.
Matsuzaki S; Uehara S; Murakami T; Fujiwara J; Funato T; Okamura K
Fertil Steril; 2000 Oct; 74(4):753-9. PubMed ID: 11020519
[TBL] [Abstract][Full Text] [Related]
6. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers.
Kahán Z; Arencibia JM; Csernus VJ; Groot K; Kineman RD; Robinson WR; Schally AV
J Clin Endocrinol Metab; 1999 Feb; 84(2):582-9. PubMed ID: 10022420
[TBL] [Abstract][Full Text] [Related]
7. Effects of an Antagonistic Analog of Growth Hormone-Releasing Hormone on Endometriosis in a Mouse Model and In Vitro.
Köster F; Jin L; Shen Y; Schally AV; Cai RZ; Block NL; Hornung D; Marschner G; Rody A; Engel JB; Finas D
Reprod Sci; 2017 Nov; 24(11):1503-1511. PubMed ID: 28205459
[TBL] [Abstract][Full Text] [Related]
8. Characterization of messenger RNA expression of estrogen receptor-alpha and -beta in patients with ovarian endometriosis.
Matsuzaki S; Fukaya T; Uehara S; Murakami T; Sasano H; Yajima A
Fertil Steril; 2000 Jun; 73(6):1219-25. PubMed ID: 10856486
[TBL] [Abstract][Full Text] [Related]
9. Presence of gonadotropin-releasing hormone and its messenger ribonucleic acid in human ovarian epithelial carcinoma.
Ohno T; Imai A; Furui T; Takahashi K; Tamaya T
Am J Obstet Gynecol; 1993 Sep; 169(3):605-10. PubMed ID: 8103967
[TBL] [Abstract][Full Text] [Related]
10. Deep Infiltrating Endometriosis and Endometrial Adenocarcinoma Express High Levels of Myostatin and Its Receptors Messenger RNAs.
Carrarelli P; Funghi L; Ciarmela P; Centini G; Reis FM; Dela Cruz C; Mattei A; Vannuccini S; Petraglia F
Reprod Sci; 2017 Dec; 24(12):1577-1582. PubMed ID: 28345488
[TBL] [Abstract][Full Text] [Related]
11. Expression of transforming growth factor alpha mRNA in benign and malignant tissues derived from gynecologic patients with various proliferative conditions.
Xynos FP; Klos DJ; Hamilton PD; Schuette V; Fernandez-Pol JA
Anticancer Res; 1992; 12(4):1115-20. PubMed ID: 1323947
[TBL] [Abstract][Full Text] [Related]
12. The influence of aging and sex hormones on expression of growth hormone-releasing hormone in the human immune system.
Khorram O; Garthwaite M; Golos T
J Clin Endocrinol Metab; 2001 Jul; 86(7):3157-61. PubMed ID: 11443181
[TBL] [Abstract][Full Text] [Related]
13. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium.
Ulaner GA; Hu JF; Vu TH; Oruganti H; Giudice LC; Hoffman AR
Int J Cancer; 2000 Feb; 85(3):330-5. PubMed ID: 10652422
[TBL] [Abstract][Full Text] [Related]
14. Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue.
Nephew KP; Choi CM; Polek TC; McBride R; Bigsby RM; Khan SA; Husseinzadeh N
Gynecol Oncol; 2000 Mar; 76(3):388-96. PubMed ID: 10684716
[TBL] [Abstract][Full Text] [Related]
15. Pyrimidine nucleoside phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.
Suzuki M; Usui N; Furugen Y; Mitsuhasi N
Int J Clin Oncol; 2001 Feb; 6(1):19-24. PubMed ID: 11706522
[TBL] [Abstract][Full Text] [Related]
16. Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary.
Bagnato A; Moretti C; Ohnishi J; Frajese G; Catt KJ
Endocrinology; 1992 Mar; 130(3):1097-102. PubMed ID: 1537276
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of analysis of estrogen and progesterone receptors in human uterine tissues].
Maleeva A; Milkov V
Akush Ginekol (Mosk); 1991 May; (5):55-7. PubMed ID: 1897675
[TBL] [Abstract][Full Text] [Related]
18. Expression of sex hormone-binding globulin mRNA in uterine leiomyoma, myometrium and endometrium of human subjects.
Misao R; Nakanishi Y; Fujimoto J; Tamaya T
Gynecol Endocrinol; 1995 Dec; 9(4):317-23. PubMed ID: 8629461
[TBL] [Abstract][Full Text] [Related]
19. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT.
Lerman H; Metser U; Grisaru D; Fishman A; Lievshitz G; Even-Sapir E
J Nucl Med; 2004 Feb; 45(2):266-71. PubMed ID: 14960646
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
